Lohocla Research

Executive Summary

Lohocla Research is a San Diego-based private biopharmaceutical company focused on developing novel small molecule therapies and diagnostics for chronic pain, neuroinflammation, and addiction. Founded in 2017, the company addresses the enormous unmet need for effective, non-addictive treatments for these debilitating conditions, which affect millions of patients worldwide and are often poorly managed by existing therapies. By targeting maladaptive nervous system pathways, Lohocla aims to provide disease-modifying options that improve quality of life while reducing the societal burden of opioid dependence and neuroinflammatory disorders. While the company operates with limited public information regarding its specific pipeline programs, its scientific focus on modulating neural signaling and inflammatory processes positions it within a high-demand therapeutic area with significant commercial potential.

Upcoming Catalysts (preview)

• TBDInitiation of first-in-human Phase 1 trial for lead candidate40% success
• TBDPublication of preclinical efficacy data in peer-reviewed journal60% success
• TBDStrategic partnership or licensing deal for diagnostic platform30% success